Dec 3 (Reuters) - AstraZeneca has signed a deal worth up to $247 million with U.S. firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. (Reporting by Shivani Tanna in Bengaluru; Editing by William Mallard)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,370 GBX | +0.31% | +2.66% | +16.70% |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,370 GBX | +0.31% | +2.66% | 240B | ||
4.91 USD | -4.47% | -3.35% | 555M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.70% | 240B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca ties up with AI biologics company to develop cancer drug - FT